ADMA Biologics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $751.07 million
- Book Value:
- Revenue TTM:
- $130.48 million
- Operating Margin TTM:
- Gross Profit TTM:
- $1.17 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ADMA Biologics Inc had its IPO on 2013-10-17 under the ticker symbol ADMA.
The company operates in the Healthcare sector and Biotechnology industry. ADMA Biologics Inc has a staff strength of 527 employees.
Shares of ADMA Biologics Inc opened at $3.13 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $3.03 - $3.18, and closed at $3.1.
This is a -0.96% slip from the previous day's closing price.
A total volume of 9,980,400 shares were traded at the close of the day’s session.
In the last one week, shares of ADMA Biologics Inc have slipped by -5.49%.
ADMA Biologics Inc's Key Ratios
ADMA Biologics Inc has a market cap of $751.07 million, indicating a price to book ratio of 7.7007 and a price to sales ratio of 5.9412.
In the last 12-months ADMA Biologics Inc’s revenue was $130.48 million with a gross profit of $1.17 million and an EBITDA of $-39803512. The EBITDA ratio measures ADMA Biologics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ADMA Biologics Inc’s operating margin was -35.64% while its return on assets stood at -10.78% with a return of equity of -69.23%.
In Q3, ADMA Biologics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 98.7%.
ADMA Biologics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ADMA Biologics Inc’s profitability.
ADMA Biologics Inc stock is trading at a EV to sales ratio of 6.2567 and a EV to EBITDA ratio of -17.4554. Its price to sales ratio in the trailing 12-months stood at 5.9412.
ADMA Biologics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $300.56 million
- Total Liabilities
- $44.44 million
- Operating Cash Flow
- Capital Expenditure
- $6.22 million
- Dividend Payout Ratio
ADMA Biologics Inc ended 2023 with $300.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $300.56 million while shareholder equity stood at $100.38 million.
ADMA Biologics Inc ended 2023 with $0 in deferred long-term liabilities, $44.44 million in other current liabilities, 19678.00 in common stock, $-465784988.00 in retained earnings and $3.53 million in goodwill. Its cash balance stood at $34.91 million and cash and short-term investments were $34.91 million. The company’s total short-term debt was $720,755 while long-term debt stood at $141.37 million.
ADMA Biologics Inc’s total current assets stands at $224.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $20.90 million compared to accounts payable of $25.20 million and inventory worth $162.91 million.
In 2023, ADMA Biologics Inc's operating cash flow was $-3380481.00 while its capital expenditure stood at $6.22 million.
Comparatively, ADMA Biologics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ADMA Biologics Inc stock is currently trading at $3.1 per share. It touched a 52-week high of $3.98 and a 52-week low of $3.98. Analysts tracking the stock have a 12-month average target price of $5.13.
Its 50-day moving average was $3.5 and 200-day moving average was $2.86 The short ratio stood at 4.72 indicating a short percent outstanding of 0%.
Around 170% of the company’s stock are held by insiders while 7770.2% are held by institutions.
Frequently Asked Questions About ADMA Biologics Inc
Similar Industry Stocks (Biotechnology)
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.